Effect of beetroot or beetroot plus vitamin C supplementation on cardiovascular function in patients with coronary artery disease: protocol for a double-blind, placebo-controlled, randomised trial

IntroductionCoronary artery disease (CAD), classified into the atherosclerosis category, is a prevalent cardiovascular disease worldwide that is associated with serious comorbidities and death. The purpose of this study was to evaluate the effect of beetroot/beetroot plus vitamin C on cardiovascular...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2022-06, Vol.12 (6), p.e061394-e061394
Main Authors: Bahrami, Leila Sadat, Mohebaty, Mohsen, Arabi, Seyyed Mostafa, Tabesh, Hamed, Nematy, Mohsen, Rezvani, Reza
Format: Article
Language:English
Subjects:
Cardiovascular disease
Chronic illnesses
Clinical trials
Coronary heart disease
Dietary supplements
Double-blind studies
HEALTH SERVICES ADMINISTRATION & MANAGEMENT
Nitrates
Nutrition
Nutrition and Metabolism
Vitamin C
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionCoronary artery disease (CAD), classified into the atherosclerosis category, is a prevalent cardiovascular disease worldwide that is associated with serious comorbidities and death. The purpose of this study was to evaluate the effect of beetroot/beetroot plus vitamin C on cardiovascular health status and function in patients with CAD.Method and analysisA randomised, placebo-controlled, double-blind clinical trial to recruit 90 patients with CAD at the cardiac outpatient clinic and Imam Reza Hospital, Mashhad, Iran. Participants will be divided into three groups: (1) Those who receive 500 mg three times a day of beetroot capsules, (2) Those who receive 500 mg three times a day of beetroot plus vitamin C capsules, and (3) Those who receive placebo capsules three times a day for 4 weeks. Pulse wave velocity, Augmentation Index, heart rate, volume of oxygen (VO2) max/VO2 peak, peak heart rate, blood pressure, interleukin 6 (IL-6), high sensitivity C reactive protein, intercellular adhesion molecule, vascular cell adhesion molecule, lipid profile and anthropometry will be measured at the beginning and end of the intervention.Ethics and disseminationThis study was approved by the Ethics Committee of Mashhad University of Medical Sciences (IR.MUMS.MEDICAL.REC.1399.717). All participants will be asked to complete the consent form at the beginning of the study. The results will be actively disseminated through peer-reviewed journals and conference presentations.Trial registration numberIranian Registry of Clinical Trials, IRCT20210217050393N1 (registered 16 May 2021).
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2022-061394